CFOTO | Future Publishing | Getty Images
Pfizer on Tuesday reported a narrower than expected adjusted loss for the third quarter as the drugmaker recorded charges largely related to struggles for its Covid antiviral treatment Paxlovid and Covid vaccine.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased